FDA Approved: DIFICID — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for DIFICID (fidaxomicin) from Merck Sharp & Dohme LLC, resulting in updated labeling under the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Dificid (fidaxomicin)

Snippet

SUPPL AP for DIFICID (FIDAXOMICIN)